ResearcherThe University of SydneyActive in the last 2 years

Nathalie B. Rasko

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5081835917. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 6

Papers, trials and grants by year

2025: 1 paper

Papers 1

FXYD3 Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict Survival. Co-author DOI 10.1002/cam4.70500 ↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Sooin Byeon · 1 shared paper, 2025 · strength 0.25
- Paper FXYD3 Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict Survival. DOI 10.1002/cam4.70500 ↗
Jaswinder Singh Samra · 1 shared paper, 2025 · strength 0.25
- Paper FXYD3 Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict Survival. DOI 10.1002/cam4.70500 ↗
Anthony James Gill · 1 shared paper, 2025 · strength 0.25
- Paper FXYD3 Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict Survival. DOI 10.1002/cam4.70500 ↗
Christopher Bahdah Nahm · 1 shared paper, 2025 · strength 0.25
- Paper FXYD3 Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict Survival. DOI 10.1002/cam4.70500 ↗
Sumit Sahni · 1 shared paper, 2025 · strength 0.25
- Paper FXYD3 Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict Survival. DOI 10.1002/cam4.70500 ↗
Anubhav Mittal · 1 shared paper, 2025 · strength 0.25
- Paper FXYD3 Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict Survival. DOI 10.1002/cam4.70500 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.